Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study

Autor: Robert N. Weinreb, Felipe A. Medeiros, Keith R Martin, Jason L Vittitow, James H. Peace, Baldo Scassellati Sforzolini

Publikováno v: American Journal of Ophthalmology. 168:250-259

Purpose To compare the intraocular pressure (IOP)-lowering effect of latanoprostene bunod (LBN) 0.024% with timolol maleate 0.5% in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT). Design Prospective, randomized, double-masked, p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20a176aca96d77f59c5f2ff4829ed1d9

Evaluation of the Effect of Latanoprostene Bunod Ophthalmic Solution, 0.024% in Lowering Intraocular Pressure over 24 h in Healthy Japanese Subjects

Autor: Robert N. Weinreb, Baldo Scassellati Sforzolini, Jason L Vittitow, Makoto Araie

Publikováno v: Advances in Therapy
Araie, M; Sforzolini, BS; Vittitow, J; & Weinreb, RN. (2015). Evaluation of the Effect of Latanoprostene Bunod Ophthalmic Solution, 0.024% in Lowering Intraocular Pressure over 24 h in Healthy Japanese Subjects. Advances in Therapy, 32(11), 1128-1139. doi: 10.1007/s12325-015-0260-y. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/5gq5x8gc
Advances in therapy, vol 32, iss 11

Introduction Latanoprostene bunod is a novel nitric oxide (NO)-donating prostaglandin F2α receptor agonist in clinical development for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. We evalua

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92a6fa88804b7c67b621ec9ec18eac6c
http://europepmc.org/articles/PMC4662725

Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study

Autor: Robert N, Weinreb, Baldo, Scassellati Sforzolini, Jason, Vittitow, Jeffrey, Liebmann

Publikováno v: Ophthalmology. 123(5)

To compare the diurnal intraocular pressure (IOP)-lowering effect of latanoprostene bunod (LBN) ophthalmic solution 0.024% every evening (qpm) with timolol maleate 0.5% twice daily (BID) in subjects with open-angle glaucoma (OAG) or ocular hypertensi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2f1fc9f0b010f1996fbff43143e5c418
https://pubmed.ncbi.nlm.nih.gov/26875002

Polypoidal choroidal vasculopathy masquerading as central serous chorioretinopathy

Autor: Richard F. Spaide, Mauro Goldbaum, K. Bailey Freund, Yale L. Fisher, Lawrence A. Yannuzzi, David R. Guyer, Dennis A. Orlock, David Maberley, John A. Sorenson, Doric Wong, Jason S. Slakter, Baldo Scassellati-Sforzolini

Publikováno v: Ophthalmology. 107:767-777

Objective To differentiate polypoidal choroidal vasculopathy (PCV) from central serous chorioretinopathy (CSC). Design A retrospective, observational case series. Participants Thirteen patients originally diagnosed with CSC proved to have PCV after m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42fc7968a80794cae4973d79f1f33b34
https://doi.org/10.1016/s0161-6420(99)00173-6

Reply to Hall J: 'Use of the Fluocinolone Acetonide Intravitreal Implant for the Treatment of Noninfectious Posterior Uveitis: 3-Year Results of a Randomized Clinical Trial in a Predominantly Asian Population'

Autor: Baldo Scassellati Sforzolini

Publikováno v: Ophthalmology and Therapy

I read with interest Dr. Hall’s letter. While the article titled “Use of the Fluocinolone Acetonide Intravitreal Implant for the Treatment of Noninfectious Posterior Uveitis (NIPU): 3-Year Results of a Randomized Clinical Trial in a Predominantly

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8d89bf96d4703ed765cbc12556d1e36
https://doi.org/10.1007/s40123-015-0030-6